Clinical Trial Update: The KHENERGYC Study [Phase 2]

View source ↗

Summary

Phase 2 KHENERGYC study for mitochondrial diseases is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leigh Syndrome
• Melas Syndrome
• Mitochondrial Diseases

Drugs mentioned

• KHENERGYC

Snippet

Sponsor: Khondrion BV | Conditions: Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Phase 2 | Status: SUSPENDED